- Home
- HURN vs ZLAB Comparison
HURN vs ZLAB Comparison
Compare HURN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- ZLAB
- Stock Information
- Founded
- HURN 2002
- ZLAB 2013
- Country
- HURN United States
- ZLAB China
- Employees
- HURN N/A
- ZLAB N/A
- Industry
- HURN Professional Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- HURN Consumer Discretionary
- ZLAB Health Care
- Exchange
- HURN Nasdaq
- ZLAB Nasdaq
- Market Cap
- HURN N/A
- ZLAB 1.8B
- IPO Year
- HURN 2004
- ZLAB 2017
- Fundamental
- Price
- HURN $115.91
- ZLAB $31.24
- Analyst Decision
- HURN Strong Buy
- ZLAB Strong Buy
- Analyst Count
- HURN 4
- ZLAB 4
- Target Price
- HURN $131.75
- ZLAB $52.50
- AVG Volume (30 Days)
- HURN 66.1K
- ZLAB 976.3K
- Earning Date
- HURN 10-29-2024
- ZLAB 11-12-2024
- Dividend Yield
- HURN N/A
- ZLAB N/A
- EPS Growth
- HURN 14.29
- ZLAB N/A
- EPS
- HURN 4.16
- ZLAB N/A
- Revenue
- HURN $1,425,021,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- HURN $11.16
- ZLAB $48.34
- Revenue Next Year
- HURN $8.65
- ZLAB $47.12
- P/E Ratio
- HURN $25.27
- ZLAB N/A
- Revenue Growth
- HURN 12.76
- ZLAB 28.16
- 52 Week Low
- HURN $84.26
- ZLAB $13.48
- 52 Week High
- HURN $115.65
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- HURN 66.87
- ZLAB 70.41
- Support Level
- HURN $103.24
- ZLAB $31.52
- Resistance Level
- HURN $108.75
- ZLAB $36.60
- Average True Range (ATR)
- HURN 2.06
- ZLAB 1.36
- MACD
- HURN 0.22
- ZLAB 0.34
- Stochastic Oscillator
- HURN 100.00
- ZLAB 58.60
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.